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MIGRATION AND DIFFERENTIATION POTENTIAL OF MESENCHYMAL
STEM CELLS FROM PATIENTS WITH LATE OSTEOARTHRITIS
TOWARDS IN SITU JOINT CARTILAGE TISSUE ENGINEERING
J. Ringe, K. Gulich, T. Dehne, K. Andreas, G.-R. Burmester,
M. Sittinger. Tissue Engineering Lab. and Berlin-Brandenburg Ctr. for
Regenerative Therapies, Dept. of Rheumatology, Charité-Univ. Med.
Berlin, Berlin, Germany
Purpose: Today, for regenerative treatment of injured or early osteo-
arthritic cartilage, ACI and MACI are clinically applied. Also mesen-
chymal stem cell based approaches have reached the clinic. Here,
AMIC combines microfracture with implantation of a collagen
membrane, and Chondrotissue microfracture with a PGA/hyaluronan
scaffold. AMIC is a passive approach; endogenous MSC ﬂow into the
membrane. Chondrotissue, in whose development we were involved,
is between passive and active; MSC ﬂow into the scaffold is enhanced by
the addition of MSC recruiting serum. Our aim is to develop an active in
situ approach, wherein the implantation of scaffolds, loaded with MSC
recruiting chemokines and differentiation factors, combined with
microfracture, allows the use of endogenous MSC to promote OA
cartilage regeneration.
Methods: MSC were isolated from bone marrow of normal donor and
OA hip joint cancellous bone and characterized (morphology, growth,
surface marker, multilineage potential). Also their Ck receptor proﬁle
was elucidated (qPCR, immunohistochemistry). Cartilage and chon-
drocytes were harvested from ND and OA femoral heads, and super-
natants were analyzed for their Ck proﬁle (protein array). Then, the
recruitment potential of supernatants and Ck on MSC was examined
(chemotaxis assay), and Pertussis toxin, siRNA and antibodies were
applied to block Ck receptors. Moreover, expression proﬁles of Ckstimulated ND and OA MSC were generated and compared (micro-
arrays). Selected Ck were also encapsulated in a PLGA release system
using the w/o/w emulsion and solvent evaporation technique, and in
vitro and in vivo applied to chemoattract superparamagnetic iron oxide
nanoparticle (SPION) labeled MSC (rat model, MRI). Finally, compara-
tive gene expression proﬁling was performed for ND and OA MSC
ﬁbrinogen/PLGA transplants after chondrogenic stimulation with
TGFß3.
Results: ND and OA MSC have a ﬁbroblast-like morphology, a similar
doubling time, differentiate to fat, bone and cartilage, are CD73, CD105
positive, and CD45 negative. Moreover, both express most Ck receptors.
Proteomics revealed similar Ck proﬁles of ND and OA cartilage super-
natants. In contrast, ND and OA chondrocyte supernatants had different
Ck spectra. Only OA supernatants were CXCL12 (SDF1) positive. In
chemotaxis assays, cartilage supernatants recruited more MSC than
chondrocyte supernatants, and OA cartilage supernatants more MSC
than ND supernatants. Based on protein arrays, CCL25 (TECK) and was
analyzed in more detail. CCL25 recruited a high number of ND and OA
MSC and represents a candidate for in situ approaches. MSC treatment
with Pertussis toxin could block supernatant induced chemotaxis,
whereas treatment with CCR9-siRNA or CCR9-antibodies (the CCL25
receptor) had only a small effect. Subsequent expression proﬁling of
CCL25 induced ND and OA MSC gave us a deep insight into the Ck
dependent mobilization of these cells. For example, 22 genes were
differentially expressed in both ND and OA MSC. Most of them are
involved in pathways related to homing (PDE4B), cytoskeletal and
membrane reorganization (IGFBP1) and movement (CXCL8, PTGS2). In
an ongoing study, CCL25 loaded PLGA particles are tested in a rat model.
Here, for in vivo MRI monitoring of MSCmigration towards CK releasing
particles, SPION labeled MSC are used. Finally, the regenerative poten-
tial of OA and ND MSC was studied in ﬁbrinogen/PLGA transplants.
Chondrogenesis resulted in ﬁbro- and joint cartilage. Moreover, ND and
OA expression proﬁles showed a similar expression of marker genes
known in context of OA (COL10A1, MMP1 and -3).
Conclusions: Here we have shown that end-stage OA MSC behave like
ND MSC, and that we have established the key knowledge and tools for
an active, MSC-based in situ therapy of injured or OA joint cartilage. In
future, addition of anti-inﬂammatory drugs may allow the use of such
approaches during inﬂammation and thus, also for other arthritic
diseases like RA.600
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OSTEOARTHRITIS IN VITRO
T. Dehne y, N. Schlichting y, K. Mans z, M. Endres x, B. Stuhlmüller z, M.
Sittinger y, C. Kaps x, J. Ringe y. y Tissue Engineering Lab. and Berlin-
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Berlin, Berlin, Germany; zDept. of Rheumatology and Clinical
Immunology, Charité- Univ.etsmedizin Berlin, Berlin, Germany;
x TransTissue Technologies GmbH, Berlin, Germany
Purpose: In vitro models are useful tools for the development of new
therapy strategies in cartilage repair. The limited availability of human
primary tissue and high costs of animal models hamper preclinical tests
of innovative substances and techniques. In this study we tested the
potential of porcine chondrocyte micromasses to mimic essential
aspects of osteoarthritis (OA) in vitro.
Methods: Primary chondrocytes were enzymatically isolated from
porcine femoral condyle and were maintained for 14 days in 96-mul-
tiwell format to establish cartilage-like extracellular matrix (ECM) in
a high-throughput scale. Subsequently, 10ng/ml recombinant porcine
tumor necrosis factor alpha (TNF-alpha) was added up to 14 days to
induce OA changes. These changes were documented on histological
(Alcian blue and Safranin O stainings histomorphometrically analyzed),
biochemical (collagens: hydroxyproline assay, proteoglycans: DMMB-
method) and gene expression level (Affymetrix porcine microarray, RT-
PCR), and were compared with data from human OA cartilage. Further,
the inﬂuence of 10 ng/ml transforming growth factor beta 1 (TGF-b1), 1
ng/ml interleukin 1 beta (IL-1b) and 5% platelet rich plasma (PRP) on
TNF-alpha induced changes was analyzed to test the performance of the
model.
Results: After 14 days in micromass culture, porcine primary chon-
drocytes developed an ECM rich in proteoglycans and collagens. On
gene expression level cartilage markers COL2A1, COMP, CSPG4 and
Aggrecan were detected. After stimulation with 10 ng/ml TNF-alpha,
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(score decline -64%) and biochemical analysis of GAG (-75%) and total
collagen (-30%) content. Gene expression of catabolic enzymes
(MMP13, MMP1, MMP2), and genes involved in inﬂammatory response
(IL8, CCL2, CCL4 CXCL2) was signiﬁcantly increased (>4-fold) and genes
related to ECM formation (COL2A1, COMP, Aggrecan, COL8A1, COL11A1)
were decreased (<-4-fold). Whereas histological and biochemical
characteristics of the TNF-alpha induced model match with observa-
tions known from human OA cartilage, gene expression analysis
revealed contrary gene expression pattern related to ECM formation
(COL2A1, COL11A1, COMP) and to hypertrophic bone formation
(COL10A1). The addition of TGF-b1 and PRP during TNF-alpha stimu-
lation led to reduced GAG loss (both 40%) whereas IL1b enhanced the
GAG loss by further 10% demonstrating responsiveness of the model to
test substances.
Conclusions: The use of porcine chondrocytes in micromasses and the
addition of TNF-alpha resulted in the induction of some typical features
of OA such as extensive ECM loss and induction of genes related to
catabolic activity and inﬂammatory response. In contrast to human OA,
ECM formation was inhibited, which might be a consequence of the
exclusive use of TNF-alpha, which is only one of many impacting factors
in OA. Although not all characteristics of human OA could be demon-
strated, the presented test system was suitable to detect effects of test
substances. TNF-alpha induced porcine micromasses can be a useful
supplement to existing preclinical tests in OA and an alternative to the
use of human tissue in vitro.
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IN VITRO CARTILAGE TISSUE ENGINEERING USING HUMAN BONE
MARROW MESENCHYMAL STEM CELLS GROWN ON DIFFERENT
COLLAGEN SCAFFOLDS
C. Sanjurjo-Rodríguez y, A.H. Martínez-Sánchez y, E. Muiños López y,
T. Hermida Gómez y, I.M. Fuentes Boquete y,z, F.J. De Toro Santos y,z,
J. Buján Varela x, S. Díaz-Prado y,z, F.J. Blanco y. yOsteoarticular and
Aging Res. Lab. CIBER-BBN. Rheumatology Div. INIBIC-CHUAC, A Coruña,
Spain; z INIBIC-Univ. of A Coruña, A Coruña, Spain; xDept. of Med.
Specialties. Univ. of Alcalá de Henares, Madrid, Spain
Purpose: To study the chondrogenic differentiation of human bone
marrow mesenchymal stem cells (hBM-MSCs) grown on different
collagen scaffolds and evaluate the resulting cartilage-like constructs.
Methods: hBM-MSCs were isolated, characterized and tested for their
multipotential capacity. hBM-MSCs were cultured on different collagen
scaffolds for 30 days in a chondrogenic differentiation medium. We
tested four scaffolds: Col I + Col II (C1C2); Col I + Col II + heparan
sulphate (C1C2HS); Col I + Col II +chondroitin sulfate (C1C2CHS); Col I +
heparin (C1OLH3). Chondrogenic differentiation was conﬁrmed by
histochemical and immunohistochemical analysis. Relative gene
expression of characteristic chondrocyte genes, SOX9 ([Sex determining
region Y]-box 9), COL II (Collagen type II, alpha 1), AGG (Aggrecan), was
performed. Furthermore, collagen assays were used to measure
collagen concentration in culture supernatants. Transmission and
scanning electronic microscopy were performed to study the cell
ultrastructure and cell morphology.
Results: hBM-MSCs were able to grow in the surface but also inside the
different types of collagen supports. The percentage of cells, regarding
the area of the analyzed support, was higher than 75% in the C1C2HS
and in the C1C2CHS, and higher than 50% in the other scaffolds tested.
Moreover, proliferation was observed by PCNA (Proliferating cell
nuclear antigen) immunostaining in all the scaffolds studied. hBM-
MSCs showed the formation of cell aggregates. Extracellular matrix of
the cells grown on all the scaffolds showed abundant proteoglycans
(Figure, A). Cells showed positive immunostaining for type II collagen in
C1C2 (Figure, A). The extracellular matrix showed positive immuno-
staining for type II collagen in C1C2HS and C1C2CHS (Figure, A).
Expression gene of COL II was also detected, along with SOX9 in all the
constructs, proving that there was an early chondrogenesis (Figure, B).
Moreover, expression of AGGwas detected in all scaffolds, but C1C2 and
C1C2HS showed the higher relative expression (Figure, B). Cells pre-
sented characteristics similar to chondrocytes, as it was shown by
scanning electron microscopy, with semispherical shape and anchors
(Figure, C). Also, it was seen extracellular matrix around the cells and
a huge amount of secretion vesicles (Figure, C). Transmission electron
microscopy showed a high secretory activity and a high amount of
mitochondrias in all cells, except in cells of C1OLH3 (Figure, C).Furthermore, we only observed extracellular matrix on C1C2CHS, pre-
senting a large organization of collagen ﬁbrils (Figure, C). The highest
total collagen concentration was detected in culture supernatants
between 11 to 21 days, showing the beginning of the differentiation.
Conclusions: Our data demonstrated that these different collagen
scaffolds were optimal for hBM-MSCs growth. hBM-MSCs cultured in
chondrogenic medium on C1C2HS and C1C2CHS scaffolds were able to
differentiate into chondrocyte-like cells and to synthesize cartilage-like
extracellular matrix. These two scaffolds are suitable candidates for
chondrogenic differentiation of hBM-MSCs, and they may be used to
construct cartilage-like tissue in vitro. Acknowledgements: B. Parma
(OPOCRIN S.P.A.); CAM (S2009/MAT-1472); CIBER BBN CB06-01-0040;
REDICENT; SAI-UDC.
Figure. A) Images obtained from the different constructs (in columns) by Safranin-
O staining and Col II immunostaining. B) On the left, it is represented/the relative
expression levels, in all the constructs, of characteristic chondrogenic genes. On
the right, it is represented the collagen concentration on the supernatant, along
the 30 days of differentiation. C) Images obtained from the different constructs (in
columns) by transmission electron microscopy (TEM) and scanning electron
microscopy (SEM).
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TISSUE ENGINEERING FOR CARTILAGE REPAIR: GROWTH AND
PROLIFERATION OF HBM-MSCS ON SCAFFOLDS COMPOSED OF
COLLAGEN I AND HEPARAN SULPHATE
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E. Muiños López y, I.M. Fuentes Boquete y,z, F.J. De Toro Santos y,z,
J. Buján Varela x, S. Díaz-Prado y,z, F.J. Blanco y. yOsteoarticular and
Aging Res. Lab. CIBER-BBN. Rheumatology Div. INIBIC-CHUAC, A Coruña,
Spain; z INIBIC -Univ. of A Coruña, A Coruña, Spain; xDept. of Med.
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Purpose: To evaluate the proliferation and chondrogenic potential of
human Bone Marrow Mesenchymal Stem Cells (hBM-MSCs) grown on
type I Collagen (Col I) and different concentrations of Heparan Sulfate
(HS) scaffolds. We also studied the quality of the neo-synthesized
cartilaginous tissue.
Methods: hBM-MSCs were cultured over the scaffolds in chondrogenic
differentiation medium (Lonza, Biowhittaker, Belgium) or DMEM with
20% FBS (Fetal Bovine Serum) for 15 and 30 days, in both cases plus 100
nM PTHrP (Parathyroid hormone-related protein). Scaffolds without
cells were cultured in chondrogenic medium as negative controls.
Chondrogenic differentiation and neosythesized cartilage quality were
evaluated by histochemical and immunohistochemical analysis,
